Daan Gene Valuation

Q: What is the Fair Price of 002030 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

002030 (CN¥6.2) is trading above our estimate of [[fair value]] (CN¥1.71)

Is 002030 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002030 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002030 (CN¥6.2) is trading above our estimate of fair value (CN¥1.71)

Significantly Below Fair Value: 002030 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002030?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 002030. This is calculated by dividing 002030's market cap by their current preferred multiple.
What is 002030's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

002030 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	8.8x
Enterprise Value/EBITDA	-25.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 002030's PS Ratio compare to its peers?

The above table shows the PS ratio for 002030 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.9x
301047 Sino BiologicalInc	13.1x	15.6%	CN¥8.4b
688105 Nanjing Vazyme Biotech	6.8x	23.8%	CN¥9.5b
688767 Hangzhou Biotest BiotechLtd	6x	n/a	CN¥3.1b
002038 Beijing SL Pharmaceutical	9.7x	n/a	CN¥7.6b
002030 Daan Gene	9.4x	n/a	CN¥8.7b

Price-To-Sales vs Peers: 002030 is expensive based on its Price-To-Sales Ratio (9.4x) compared to the peer average (8.9x).

Price to Earnings Ratio vs Industry

How does 002030's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	44.0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	44.0%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 002030 is expensive based on its Price-To-Sales Ratio (9.4x) compared to the CN Biotechs industry average (7.3x).

Price to Sales Ratio vs Fair Ratio

What is 002030's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002030 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	9.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 002030's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.